Why clinical development’s next AI bottleneck is not the model, but the system around it.
|Articles|August 16, 2006
KEY SFBC MIAMI ASSETS ACQUIRED BY ALLIED RESEARCH INTERNATIONAL
Allied Research International (ARI), Canada's leading contract research organization (CRO), announced today that it has acquired key assets of South Florida Bioavailability Clinic International's (SFBC) Miami, Florida operations.
Advertisement
TORONTO – August 16, 2006 – Allied Research International (ARI), Canada's leading contract research organization (CRO), announced today that it has acquired key assets of South Florida Bioavailability Clinic International's (SFBC) Miami, Florida operations. The acquired assets include a fully-functional clinical laboratory and equipment, and a 46-station cardiac monitoring suite.
"These assets will be re-located to ARI's new state-of-the-art, 150-bed Phase 1 clinic in Miami that opened this spring. ARI will also employ selected leading staff from SFBC's Miami operations," said Dr. Piyush Patel MD, CEO and Founder of ARI.
ARI now has significantly expanded capacity to perform complex Phase 1 and special population studies in the Miami area, There is a large need for these types of studies and for which few other CROs specialize.
The expanded facilities in Miami add to ARI's 80-bed Phase 1 unit in Toronto, Canada, bringing its total capacity to over 230 Phase I beds.
Advertisement
Related to this article
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more than sourcing strategy, and how early readiness signals predict trial risk.
FDA Opens Applications for Expedited IND Pilot Designed to Accelerate First-in-Human Trial Timelines
The pilot pairs drug sponsors with qualified research institutions to compress the path from drug identification to first-in-human study through rolling submission review and earlier coordination of institutional review board and site activation activities.
A Syneos Health-announced study from Tufts Center for the Study of Drug Development finds no single sourcing model consistently outperforms others, pointing instead to vendor coordination, governance, and fit-for-purpose design as the real performance drivers.
Regulatory expectations for patient input in drug development have shifted from aspiration to documented methodology across three major jurisdictions.
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, outlines what it takes to move beyond transactional engagement and treat patient advocacy organizations as long-term partners in the science and the care.
In today's ACT Brief, we examine what families with rare epilepsy teach about trial feasibility, how preclinical CRO partnerships are evolving beyond transactional services, and why cortisol dysregulation limits GLP-1 effectiveness in diabetes.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Benchmarking Study Finds Clinical Trial Performance Is Shaped by Operating Model Design, Not Sourcing Strategy
2
The Execution Gap: Why Clinical Trial Infrastructure Has to Be Built Before AI Can Deliver
3
Operationalizing the Patient Voice: Converging U.S., EU, and UK Requirements and the Role of Real-World Patient-Reported Data
4
FDA Opens Applications for Expedited IND Pilot Designed to Accelerate First-in-Human Trial Timelines
5